Covered recipient · General Payments record
LALIT ANEJA
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,426.83
128 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,401.25 | 126 |
| Education | $25.58 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LALIT ANEJA
NPI 1386989820 · CMS profile ID 1717328
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
NORTH VENICE, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1386989820?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386989820?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386989820?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- LALIT ANEJA, NPI 1386989820, CMS profile ID 1717328, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1386989820?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
128 matching records · $2,426.83 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–128 of 128.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.70 | 04/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893502197 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.64 | 04/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955585469 | CMS |
| Merck Sharp & Dohme LLC | $16.32 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944538233 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $20.03 | 03/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942296817 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.63 | 03/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810443 | CMS |
| Lilly USA, LLC | $22.58 | 03/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918165287 | CMS |
| Genentech USA, Inc. | $15.65 | 03/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950789417 | CMS |
| Lilly USA, LLC | $22.99 | 03/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918126561 | CMS |
| Novartis Pharmaceuticals Corporation | $13.46 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893502195 | CMS |
| Genentech USA, Inc. | $22.33 | 03/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950766393 | CMS |
| BeiGene USA, Inc. | $26.90 | 03/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940794029 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.37 | 03/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810429 | CMS |
| Dendreon Pharmaceuticals LLC | $39.91 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943096413 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.28 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810427 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.92 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810433 | CMS |
| Novartis Pharmaceuticals Corporation | $20.42 | 03/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893502193 | CMS |
| PFIZER INC. | $14.93 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949086481 | CMS |
| ADC Therapeutics America, Inc. | $21.55 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1060941979 | CMS |
| EISAI INC. | $17.50 | 02/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 908055929 | CMS |
| Dendreon Pharmaceuticals LLC | $14.68 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943096409 | CMS |
| Dendreon Pharmaceuticals LLC | $12.79 | 02/23/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943096411 | CMS |
| E.R. Squibb & Sons, L.L.C. | $18.72 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810425 | CMS |
| Celgene Corporation | $17.93 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810431 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.27 | 02/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929857389 | CMS |
| Celgene Corporation | $19.61 | 02/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810423 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $20.00 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930603909 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.32 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915600591 | CMS |
| Celgene Corporation | $12.63 | 01/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932810559 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $166,698.43 | 23 |
| PY2024 | Principal investigator | $62,293.78 | 2 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
23 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,000.00 | 12/31/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) | No dispute reported | 06/30/2026 | 1185538765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,719.00 | 12/22/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175329744 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,818.00 | 12/19/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175329695 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 12/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | KRAS combo ph1b | No dispute reported | 06/30/2026 | 1211649968 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 11/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 11/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175327522 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,500.00 | 11/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328641 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,000.00 | 11/13/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175329288 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $361.69 | 11/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1223288119 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 10/17/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175328715 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 09/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175327952 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,100.00 | 09/08/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175329733 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,912.67 | 08/18/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175327071 |
| Principal investigator 1 | Genentech, Inc. | $4,063.00 | 08/04/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211649070 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,330.00 | 07/28/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175329200 |
| Principal investigator 1 | Genentech, Inc. | $596.00 | 07/07/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS | No dispute reported | 06/30/2026 | 1211649065 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $596.00 | 06/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1223280760 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,285.00 | 05/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185538767 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,000.00 | 05/14/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185538761 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,967.07 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185538757 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,750.00 | 04/30/2025 | Non-covered Recipient Entity FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185538769 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $27,600.00 | 02/05/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185538759 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,900.00 | 01/15/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185538763 |